The safety of biologic therapies in RA-associated interstitial lung disease (Q38173669)

30 August 2017

title

The safety of biologic therapies in RA-associated interstitial lung disease (English)

1 reference

30 August 2017

Meghna Jani

1

0 references

William Dixon

object named as

William G Dixon

series ordinal

4

0 references

author name string

Nik Hirani

series ordinal

2

1 reference

30 August 2017

Eric L Matteson

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

24 December 2013

1 reference

Nature Reviews Rheumatology

30 August 2017

published in

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

284-294

1 reference

Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Lung injury linked to etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Rituximab-induced lung disease: A systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

[A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

A case of organizing pneumonia induced by tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Interstitial lung disease following certolizumab pegol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Fatal fibrosing alveolitis with certolizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Severe interstitial lung disease following treatment with certolizumab pegol: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Association between anti-TNF-α therapy and interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Non-infectious pulmonary toxicity of rituximab: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

The MRC breathlessness scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

A clinician's guide to the diagnosis and treatment of interstitial lung diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

A multidimensional index and staging system for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Radiological versus histological diagnosis in UIP and NSIP: survival implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Update in diffuse parenchymal lung disease 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Interstitial lung disease in systemic sclerosis: a simple staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

[Diffuse idiopathic interstitial pneumonias. International multidisciplinary consensus classification by the American Thoracic Society and the European Respiratory Society, principal clinico-pathological entities, and diagnosis]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Safe use of antirheumatic agents in patients with comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

European biologicals registers: methodology, selected results and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Rituximab-induced pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Rheumatoid arthritis treatment and the risk of severe interstitial lung disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

FDA guidance on patient reported outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician- and Patient-Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical T

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.197

Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease

31 March 2020

1 reference

12 December 2020

Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis

1 reference

12 December 2020

A case of etanercept-induced pneumonitis

1 reference

12 December 2020

The OMERACT filter for Outcome Measures in Rheumatology

1 reference

12 December 2020

Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice

1 reference

12 December 2020

Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.197

1 reference

Dimensions Publication ID

30 August 2017

1010146076

0 references

1 reference